DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 1745--------------------------------------------------
       (Abst.) Role of Tysabri in MS treatment: benefits and risks
       By: agate Date: July 7, 2017, 9:20 pm
       ---------------------------------------------------------
       From Therapeutic Advances in Neurological Disorders, June 23,
       2017:
       [quote]The role of natalizumab in the treatment of multiple
       sclerosis: benefits and risks
       Barry A. Singer
       Natalizumab, a monoclonal antibody that blocks lymphocyte
       infiltration in the central nervous system, is a valuable tool
       in the treatment of relapsing forms of multiple sclerosis (MS).
       In a phase III clinical trial comparing natalizumab with placebo
       over 2 years, natalizumab reduced annualized relapse rate by
       68%, 12-week confirmed disability progression by 42%, and
       reduced contrast-enhancing lesions by 92%. In post hoc analyses,
       natalizumab treatment was associated with 37% of patients
       achieving no evidence of disease activity (versus 7% on placebo)
       and 30% achieving sustained disability improvement (versus 19%
       on placebo).
       Natalizumab did not achieve a statistically significant primary
       composite disability outcome in a trial of 887 patients with
       secondary progressive MS, but it did demonstrate a benefit on a
       prespecified component of the 9-Hole Peg Test.
       The greatest risk of natalizumab treatment is progressive
       multifocal leukoencephalopathy (PML), with a 23% mortality rate.
       Risk stratification on the basis of immunosuppressant exposure,
       natalizumab treatment duration and anti-John Cunningham virus
       (JCV) antibody status and index has greatly improved clinical
       decision making. Other potential serious natalizumab-associated
       risks reported in clinical trials and postmarketing settings
       include infusion reactions, hepatotoxicity and rare, serious
       opportunistic infections.
       With more than a decade of continuous postmarketing experience,
       natalizumab remains a very effective option for patients with
       relapsing forms of MS. To optimize appropriate selection of
       natalizumab for patients with relapsing MS, however, a thorough
       understanding of individual patient risk factors for PML or
       other adverse events is also required.[/quote]
  HTML http://journals.sagepub.com/doi/abs/10.1177/1756285617716002
  HTML http://journals.sagepub.com/doi/abs/10.1177/1756285617716002
       *****************************************************